Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials



Rating:

Share or cite this content

Citations should be made in the following way:
G. Brusselle (Ghent, Belgium), A. Papi (Ferrara, Italy), B. Chipps (Sacramento, CA, United States of America), J. Msihid (Chilly-Mazarin, France), J. Jacob-Nara (Bridgewater, NJ, United States of America), Y. Deniz (Tarrytown, NY, United States of America), P. Rowe (Bridgewater, NJ, United States of America), R. Gall (Tarrytown, NY, United States of America), B. Ortiz (Tarrytown, NY, United States of America), M. Djandji (Cambridge, MA, United States of America), A. Radwan (Tarrytown, NY, United States of America). Efficacy of dupilumab in patients with oral corticosteroid (OCS)-dependent, severe asthma with and without an allergic phenotype: phase 3 LIBERTY ASTHMA VENTURE. 2521

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in LIBERTY ASTHMA VENTURE Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021 Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: LIBERTY ASTHMA QUEST Study Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Evaluation and control of allergic rhinitis in patients with asthma (CARINA) in Korea Source: Eur Respir J 2007; 30: Suppl. 51, 382s Year: 2007 Montelukast reduces viral-induced asthma exacerbations: the PREVIA study Source: Eur Respir J 2004; 24: Suppl. 48, 212s Year: 2004 Dysinapsis in COPD and ASTHMA Source: Eur Respir J 2003; 22: Suppl. 45, 416s Year: 2003 Exacerbation burden in mild asthma: Evidence from the NOVELTY study Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Self-titration of inhaled corticosteroid and ß2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial Source: Eur Respir J, 56 (4) 2000170; 10.1183/13993003.00170-2020 Year: 2020 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort Source: Eur Respir J, 58 (3) 2003927; 10.1183/13993003.03927-2020 Year: 2021 Eosinophilic phenotype classification of patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Adherence to FDC Budesonide/Formoterol treatment and lung function of Greek asthmatic patients–COMPLETE study Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021